Carvykti

Product

Last mentioned: Mar 10, 2026

Timeline

  1. Pipeline Update

    Initial Phase 1 data released for LB2102 in solid tumors at a major medical conference.

  2. Manufacturing Expansion

    Obelisc facility in Belgium reaches full operational status for clinical and commercial supply.

  3. FY 2025 Earnings

    Legend Biotech reports full-year results and commercial highlights.

Stories mentioning Carvykti 1

pharma Neutral

Legend Biotech Reports Robust 2025 Growth Driven by Carvykti Scaling

Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.

2 sources